Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.
Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which sets up a different picture from what the share price alone might suggest. Recent headlines around the ZEUS trial setback and legal action against Eli Lilly have sharpened the focus on whether the current price fairly reflects the risks and opportunities. The share price decline of 36.4% over three years points to a period where investors who bought...
And it will likely be the first company in the sector to get there.
The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.
Companies that have reported in the Q2 cycle are offering encouraging reads on order trends, margin resilience, and full-year demand. This fundamental health is filtering directly into analyst models, driving a steady stream of upward revisions for Q3 and beyond.
Most of what Cramer says on the "Mad Money" Lightning Round is fast and directional. Occasionally, he drops a framework that reveals how he actually thinks about investing, not just trading. When a caller asked about Eli Lilly (LLY) on Tuesday, July 28, Cramer did not give a buy or sell, according ...
The global market for obesity drugs is soaring, yet Lilly has a dominant market share.
Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.
(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapUS Strikes Iran Again as Conflict Spreads Across Middle Ea
Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.
AMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.
The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.
Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The investment will support Resilience’s advanced manufacturing operations in Cincinnati.
This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S
MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?
Expansion adds at least 400 jobs, taking Resilience's Ohio headcount above 1,400
Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...
Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
